Research background
The SARS-CoV-2 nucleocapsid protein is expressed at high abundance during infection and is markedly more conserved across variants than the spike glycoprotein, which has kept it in view as a target for T-cell-directed vaccine design and for immune monitoring that is robust to antigenic drift. Peptides derived from nucleocapsid are therefore among the more frequently used reagents in CD8+ T-cell studies of coronavirus immunity.
Szeto and colleagues carried out a systematic structural and biophysical survey of nucleocapsid peptides presented by HLA-A*02:01, the most common class I allele in many populations. Eight candidate peptides were characterized and six peptide-HLA crystal structures were determined. GMSRIGMEV, corresponding to nucleocapsid residues 316 to 324, formed a complex with a thermal midpoint of 49.0 degrees Celsius, placing it in the moderately stable range among the panel, and its structure was solved at 1.40 angstrom resolution and deposited as PDB entry 7KGP. In that structure the peptide lies comparatively flat in the antigen-binding cleft, with the isoleucine at position 5 and the methionine at position 7 only partially buried between the peptide backbone and the HLA alpha-2 helix rather than projecting prominently toward a T-cell receptor.
Functionally, the same study classed this peptide as weakly immunogenic in convalescent COVID-19 donors, with responses detected in 2 of 11 individuals tested. That combination of properties is what makes the peptide useful experimentally: it is a well-characterized, structurally defined ligand whose biophysical stability is decoupled from strong population-level T-cell reactivity. Reagents of this kind serve as informative comparators in panels assembled to benchmark epitope prediction algorithms, which frequently rank peptides by predicted binding alone, and in studies asking which structural features of a peptide-MHC surface actually drive receptor engagement. Broader surveys of the SARS-CoV-2 T-cell epitope landscape place this peptide within the nucleocapsid-derived set catalogued for HLA-A*02:01.
Structural and thermal-stability evidence for peptide presentation should not be read as a prediction of strong T-cell responses in any given donor cohort.
Research applications
- Refolding of HLA-A*02:01 complexes for crystallography, referenced against the 1.40 angstrom structure 7KGP
- Differential scanning fluorimetry and thermal stability measurement of peptide-HLA complexes
- Multimer assembly for detection of nucleocapsid-specific CD8+ T cells in convalescent or vaccinated cohorts
- ELISpot and cytokine-based screening panels covering conserved SARS-CoV-2 nucleocapsid epitopes
- Benchmarking and validation of class I epitope prediction algorithms against measured binding and immunogenicity
- Comparative studies of peptide conformation and receptor accessibility within the HLA-A*02:01 cleft
- Variant conservation analyses using nucleocapsid-derived epitopes as drift-resistant reference antigens
References
- Szeto C, Chatzileontiadou DSM, Nguyen AT, et al. The presentation of SARS-CoV-2 peptides by the common HLA-A*02:01 molecule. iScience (2021) 24:102096. doi:10.1016/j.isci.2021.102096
- Crystal structure of HLA-A*02:01 in complex with SARS-CoV-2 N 316-324, 1.40 angstrom resolution. PDB 7KGP
- A systematic review of T-cell epitopes defined from the proteome of SARS-CoV-2 (2022). PMC9757803
- Seeing the T cell immunity of SARS-CoV-2 and SARS-CoV: believing the epitope-oriented vaccines. International Journal of Biological Sciences (2023) 19:4052. IJBS 2023;19:4052
Related MHC class I epitope peptides
For research use only. Not for use in diagnostic or therapeutic procedures, or for human or veterinary use.
